New Report Explores on Malaria - Pipeline Review, H2 2016
Malaria - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Malaria (Infectious Disease) pipeline landscape.
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.
To access full report with TOC, please visit Malaria - Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Malaria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 62 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14, 46 and 41 molecules, respectively.Malaria.
Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG Acetylon Pharmaceuticals, Inc. Actelion Ltd Agilvax Inc Akshaya Bio Inc. Allergy Therapeutics Plc Amura Holdings Limited Anacor Pharmaceuticals, Inc. Artificial Cell Technologies, Inc. AstraZeneca Plc Bharat Biotech International Limited Callaghan Innovation Research Ltd. Carna Biosciences, Inc. CEL-SCI Corporation Celgene Corporation Cellceutix Corporation Chong Kun Dang Pharmaceutical Corp. Cilian AG Daiichi Sankyo Company, Limited DesignMedix, Inc. Eisai Co., Ltd. GenVec, Inc. Genzyme Corporation GlaxoSmithKline Plc Hager Biosciences, LLC Horizon Pharma Plc iBio, Inc. Imaxio SA Immtech Pharmaceuticals, Inc. Immunovaccine Inc IPCA Laboratories Limited IRBM Science Park SpA Jenrin Discovery, Inc. Jomaa Pharma GmbH Kancera AB Kymab Limited Lipocure Ltd. Lipotek Pty Ltd. LondonPharma Ltd Merck & Co., Inc. Merck KGaA MerLion Pharmaceuticals Pte Ltd Microbiotix, Inc. Mitsubishi Tanabe Pharma Corporation Mucosis B.V. Mymetics Corporation Novartis AG PaxVax, Inc. Pfenex Inc. Pfizer Inc. Protein Potential, LLC Rodos BioTarget GmbH Sanaria Inc. Sanofi SBI Pharmaceuticals Co., Ltd. Selecta Biosciences, Inc. Sigma-Tau S.p.A. Takeda Pharmaceutical Company Limited Telormedix SA Tomegavax, Inc. VLP Biotech, Inc. VLP Therapeutics, LLC Zydus Cadila Healthcare Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 01:38
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home